New commercial model in the works at GSK
Executive Summary
GlaxoSmithKline is jumping on the bandwagon to restructure as the sales environment shifts. CEO Andrew Witty says the company is remodeling its U.S. operations, but did not offer specifics during a third quarter earnings call Oct. 22. The firm continues to take a hit from generic competition in the U.S. and the Avandia (rosiglitazone) controversy (1"The Pink Sheet," June 16, 2008, p. 25)